Amgen China R&D Head Mingqiang Zhang On R&D Inroads In China: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
Amgen China R&D Head Mingqiang Zhang talked with PharmAsia News along the sidelines of the PharmAsia Summit Shanghai about the company’s R&D strategy in China. Amgen’s strategy includes partnering with local research institutions, accelerating introduction of its portfolio in China and beefing up its local discovery capability.